Skip to main content
Figure 4 | Journal of Translational Medicine

Figure 4

From: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

Figure 4

Evaluation of Tc1/Th1 immune responses to melanoma and viral/recall antigens. A. Before exosome vaccination (W1). B. After exosome inoculation (W7). PBMC obtained at baseline (W1) and after 4 exosome injections are cultured 48 h with the immunizing melanoma antigens i.e Mage 3.A1/B35 or Mage3.DP04 (5 μg/ml) or with viral/recall control antigens (FluMP.A1, HIV.A1, EBV.B35, tetanus anatoxin, tuberculin) or with PHA. The three first patients were also assayed with the universal MHC class II restricted TT peptide. The specific T cell response in each of the evaluated patients is expressed as the number of IFNγ spot forming unit/5 × 105 PBMC.

Back to article page